BHC
BAUSCH HEALTH (BHC)
NYSE
$4.80+$0.13 (+2.76%)
Price as of Jun 23, 2026 8:00 PM EDT
  • $1.7B
    Market Cap
  • -23.44%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: 30
  • Momentum Score: 44
  • True Yield: N/A
  • Financial Health Score: 0
TradeSmith Loading

Latest Research & News

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.

05/04/2026, 1:00 PM • GlobeNewswire

Why Bausch Health Companies Was Crawling Higher This Week

Bausch Health Companies reported Q1 2026 earnings that beat analyst expectations with $2.52 billion in revenue (up 12% YoY) and non-GAAP net income of $0.78 per share (up 35% YoY), exceeding consensus estimates of $2.42 billion and $0.68 per share respectively. The company maintained its full-year 2026 guidance and highlighted 12 consecutive quarters of revenue growth, driving the stock up nearly 2% for the week.

05/01/2026, 1:09 AM • The Motley Fool

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight

The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.

04/20/2026, 1:00 PM • GlobeNewswire

Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic Demand

The global dermatology devices market is projected to grow from $14.4 billion in 2024 to $25.6 billion by 2030, with a CAGR of 10.4%. Growth is driven by rising skin cancer incidence, aging populations, aesthetic procedure demand, and technological innovations including picosecond lasers and 3D bioprinting. North America leads with 52.3% market share.

04/13/2026, 1:21 PM • GlobeNewswire

Scar Treatment Market Size is Expected to Reach USD 56.30 Billion by 2033; Growth is Propelling Due to the Surging Awareness for Advanced Cosmetic and Reconstructive Procedures Globally

The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.

02/18/2026, 4:00 AM • GlobeNewswire

Energy-Based Aesthetic Devices Market Research Report 2026-2031: Advancements in Laser and RF Systems, Rising Consumer Demand and Geographic Expansion Accelerate Revenue Opportunities

The Energy-Based Aesthetic Devices Market is projected to grow from USD 7.03 billion in 2025 to USD 11.80 billion by 2031 at a CAGR of 9.02%. Growth is driven by increased demand for hair removal treatments, med-spa expansion, minimally invasive procedures, and AI integration. Laser-based technology dominates the market, with North America leading globally. Key challenges include rising health and wellness awareness and high device costs.

02/17/2026, 4:58 AM • GlobeNewswire

Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - SNS Insider

The global ophthalmic drugs market is projected to grow from USD 37.35 billion in 2023 to USD 62.74 billion by 2032, driven by increasing eye disorders, advanced drug delivery methods, and rising healthcare awareness.

12/07/2025, 8:05 AM • GlobeNewswire

Why Bausch Health Companies Stock Rocketed 11% Higher Today

Bausch Health Companies' stock rose 11% after acquiring Wuhan Shibo Zhenmei Technology, a distributor of its aesthetic products in China, which enhances its market presence in the region.

12/01/2025, 7:02 PM • The Motley Fool

Biggest Stock Movers Today, Dec. 1: BHC, SMR, & More

Stock markets experienced a mixed day with major indexes declining, while individual stocks showed significant movements. Healthcare and technology stocks saw notable performance changes, with some companies experiencing substantial gains or losses.

12/01/2025, 4:34 PM • The Motley Fool

5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds

The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like user growth, economic recovery, and strategic improvements in their respective industries.

10/31/2025, 1:48 PM • Investing

5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds

The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like market overreactions, innovative strategies, and sector recovery.

10/31/2025, 11:32 AM • Investing

5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds

The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like technological innovation, market recovery, and strategic business improvements.

10/31/2025, 10:07 AM • Investing

5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds

An analysis of five stocks trading under $10 that show potential for significant price appreciation, highlighting their current challenges and future growth opportunities across social media, gaming, pharmaceuticals, fast food, and airline industries.

10/31/2025, 7:34 AM • Investing

Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners

Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.

09/10/2025, 11:30 PM • GlobeNewswire

Basal Cell Carcinoma Treatment Market to Reach USD 9.01 Billion by 2034, Reports Towards Healthcare

The global basal cell carcinoma treatment market is expected to grow from USD 3.33 billion in 2024 to USD 9.01 billion by 2034, with a CAGR of 10.48%. North America dominates the market, and technological advancements in treatment are driving market expansion.

09/09/2025, 10:00 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$4.61
$4.75
$4.67
1-Year Range
$4.67
$8.34
$4.67
Latest Close$4.67
Change
-$0.10 (-2.14%)
Volume2,902,365
Market Cap$1.7B
Shares Outstanding374.0M
P/E (TTM)-1.45
Diluted EPS (TTM)-$3.21
Enterprise Value$21.2B

Information as of 06/22/2026

Company Profile

BAUSCH HEALTH COMPANIES INC
BAUSCH HEALTH COMPANIES INC
https://www.bauschhealth.com
$1.7B
Market Cap
-$1.2B
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
2150 St. Elzéar Blvd. West, Laval, QC, Canada, H7L 4A8
514 744 6792

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Key Executives

  • Thomas J. Appio
  • Jean-Jacques Charhon
  • Seana Carson
  • Aimee J. Lenar
  • Steven Lee

Current Ownership Distribution

  • Institutions4.8B (85.38%)
  • Insiders440.1M (7.79%)
  • Mutual Funds386.1M (6.83%)
  • Other0 (0.00%)